Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia
- Xianfeng Zha†1,
- Xiaojuan Yan†1,
- Qi Shen1,
- Yuping Zhang2,
- Xiuli Wu1,
- Shaohua Chen1,
- Bo Li1,
- Lijian Yang1,
- Suxia Geng3,
- Jianyu Weng3,
- Xin Du3 and
- Yangqiu Li1, 4Email author
© Zha et al.; licensee BioMed Central Ltd. 2012
Received: 25 September 2012
Accepted: 4 December 2012
Published: 10 December 2012
A previous study has demonstrated a significant decrease in the TCRζ gene expression level in chronic myeloid leukemia (CML); thus, we further investigated the expression of TCRζ-regulating factors, the distribution of the TCRζ 3' untranslated region (3'-UTR) splice variants, and the expression level and correlation of the alternative splicing factor/splicing factor 2 (ASF/SF-2), FcεRIγ and ZAP-70 genes. TCRζ 3'-UTR splice variants were identified in peripheral blood mononuclear cells (PBMCs) from 14 healthy individuals, 40 patients with CML and 22 patients with CML in complete remission (CML-CR) by RT-PCR. The expression level of the TCRζ, FcεRIγ, ASF/SF-2 and ZAP-70 genes was analyzed by real-time quantitative PCR. While the expression of TCRζ gene in the CML group was significantly lower than that in the healthy individual and CML-CR groups, a significantly higher expression of the FceRIγ and ASF/SF-2 genes was found in the CML group. Two types of splicing forms were detected in all of the healthy individual CML-CR cases: wild type (WT) TCRζ 3'-UTR and alternatively splieced (AS) TCRζ 3'-UTR which have been alternatively splieced in the WT TCRζ 3'-UTR . However, 35% of the CML cases contained only the wild type TCRζ 3'-UTR isoform. Based on the TCRζ 3'-UTR isoform expression characteristic, we divided the patients with CML into two subgroups: the WT+AS- CML group, containing patients that express only the wild type TCRζ 3'-UTR, and the WT+AS+ CML group, which contained patients that expressed two TCRζ 3'-UTR isoforms. A significantly different ASF/SF-2 and FcεRIγ gene expression pattern was found between the WT+AS- and WT+AS+CML groups. We concluded that defective TCRζ expression may be characterized in the WT+AS-and WT+AS+CML subgroups by the different gene expression pattern. The overexpression of ASF/SF2, which alternatively splices the TCRζ 3’-UTR, is thought to participate in feedback regulation. The characteristics of TCRζ 3'-UTR alternative splicing may be a novel immunological marker for the evaluation of the CML immune status.
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disease that is characterized by the Philadelphia chromosome (Ph), which is generated by the reciprocal translocation t(9;22)(q34;q11) that results in the fusion of the c-abl oncogene 1 (ABL1) with the breakpoint cluster region (BCR) gene. T cell immunodeficiency including thymic output function, abnormal T cell receptor (TCR) repertoire expression and, in part, abnormal TCR signal transduction, such as that involving the TCRζ chain is found in patients with CML[2–6], and T cell function becomes suppressed as the disease progresses in some patients.
The TCR/CD3 complex plays a central role in T cell activation. This complex comprises of two chains, αβ or γδ, these chains are noncovalently associated with CD3 subunits, which include four transmembrane proteins: CD3γ, CD3δ, CD3ε and CD3ζ (also referred to as TCRζ). These subunits are known to form three distinct dimers, CD3γε, CD3δε, and CD3ζζ, to mediate TCR signal transduction[7–10]. There are four tyrosine kinase families involved in TCR signal transduction including the Csk, Src, Tec, and ZAP-70 (CD3 zeta chain associated protein kinase 70 kDa) kinase families. ZAP-70 is a cytosolic protein that is recruited to the T cell plasma membrane following TCR stimulation and binds to phosphorylated TCRζ immunoreceptor tyrosine-based activation motifs (ITAMs); it plays a critical role in activating downstream T cell signal transduction pathways following TCR engagement. There is evidence that the Fce receptor type Iγ (FcεRIγ) chain, which is a member of the TCRζ chain protein family and a component of the high-affinity IgE receptor, can replace a functionally deficient TCRζ chain and facilitate TCR/CD3 complex-mediated signaling[12, 13].
The absence of the TCRζ chain not only influences the TCR expression on the cell membrane and the number of single positive (i.e., CD4+ or CD8+) circulating T cells, it also impairs the proliferative response and the mature T cell activation level. T cells from patients with leukemia are functionally impaired, and this is related to decrease TCRζ chain expression[2, 3, 5, 14]. Recently, we has reported the expression pattern of the four CD3 genes in patients with AML and CML[2, 4, 5, 15], and it has been reported that the aberrant TCRζ chain expression found in the T cells of patients with systemic lupus erythematosus (SLE) may be associated with the decreased stability and translation of a TCRζ mRNA with an alternatively spliced 3'-untranslated region. However, the mechanism of TCRζ deficiency in T cells in patients with cancer remains unclear.
The TCRζ gene spans 31 kb in the chromosome 1q23.1 locus and has eight exons that are separated by introns ranging from 700 bp to greater than 8 kb[17, 18]. The TCRζ mRNA is a 1,472 kb spliced product of the eight exons with a 492 bp coding region and a long downstream 906 bp 3'-untranslated region (UTR), which is encoded by exon VIII. The stability of the TCRζ mRNA is mainly influenced by the downstream 3’ untranslated region and poly A tail. The 906 bp TCRζ 3'-UTR has several polyadenylation sites. Exon VIII comprises 20 amino acids of the carboxy-terminus and the 3'-UTR of TCRζ chain. Recently, it has been reported that there are several TCRζ chain isoforms with different 3'-UTR nucleotide sequences in mouse T cells. The activation of alternative splicing within the 3'-UTR through two internal (5' and 3') splice sites results in a splice deletion of 562 bases (nucleotides 672–1233), leading to the generation of a 344 bp alternatively spliced (AS) variant. The 344 bp AS TCRζ isoform lacks two critical regulatory adenosine/uridine-rich elements (ARE) and a translation regulatory sequence. The stability and translation of this isoform are significantly lower than that of the 906 bp WT TCRζ isoform; consequently, the relative amount of TCRζ protein generated by the AS isoform is significantly lower than that from the WT isoform[22, 23].
T cells from healthy individuals predominantly express the wild type (WT) isoform, whereas an increased level of the AS isoform was reported in T cells from SLE patients. Frequent mutations/polymorphisms and aberrant splicing of the downstream 3'-UTR may affect the stability and/or transport of the TCRζ chain mRNA, leading to its downregulation in SLE T cells. Although differential expression of the TCRζ 3'-UTR isoforms contributes to differential TCRζ protein expression levels, the factor(s) regulating the alternative splicing of the TCRζ 3'-UTR is unknown.
Alternative splicing is a powerful gene regulation mechanism that results in the generation of numerous transcripts and proteins from a single gene. Splice site selection is regulated by cis-acting elements such as intronic and exonic splicing enhancer and silencer sequences, respectively[25, 26]. Alternative splicing factor/splicing factor 2 (ASF/SF2) is a prototypical SR protein that was originally identified in HeLa nuclear extract as a factor required to reconstitute splicing in S100 cellular extract[27, 28] and influence alternative splicing site selection in a concentration-dependent manner[28, 29]. ASF/SF2 acts early during spliceosome assembly and participates in multiple steps during constitutive splicing and the regulation of alternative splicing by interacting with the pre-mRNAs and/or other splicing factors[28, 30, 31]. ASF/SF2 regulates the alternative splicing of eukaryotic genes such as caspase-9 and the T cell differentiation marker CD45[19, 32, 33]. Recently, the involvement of ASF/SF2 in the post-transcriptional regulation of TCRζ was described in T cells from patients with SLE. ASF/SF2 binds to the 3'-UTR of TCRζ and regulates the shift in alternative splicing from the AS to the WT isoform and regulates TCRζ protein expression.
Based on our previous finding that the TCRζ chain gene expression level was significantly decreased in CML, we further investigated the expression pattern of the TCRζ regulating factors TCRζ 3'-UTR and ASF/SF-2, as well as the expression level and correlation of FcεRIγ and ZAP-70, to evaluate the ASF/SF-2 regulating effects of TCRζ 3'-UTR formation.
Materials and methods
Forty newly diagnosed, untreated chronic phase CML patients, including 27 males and 13 females (13–71 years old; median age: 44 years), and 22 patients with CML complete remission ( 16 cases after allo-HSCT and 6 cases after imatinib therapy) were included in this study. The BCR-ABL fusion gene was detected in all samples by RT-PCR. Fourteen healthy individuals including 8 males and 6 females (23–53 years old; median age: 28.5 years) served as controls. Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized venous blood by Ficoll-Paque gradient centrifugation. All procedures were conducted according to the guidelines of the Medical Ethics Committee of the Health Bureau of the Guangdong Province in China.
RT-PCR for TCRζ 3′-UTR amplification
List of primers used for PCR analysis
906 bp/344 bp
473 bp/273 bp
Real-time quantitative reverse transcription–polymerase chain reaction (qRT–PCR)
The expression level of the TCRζ, FcεRIγ, ASF/SF-2, ZAP-70, and β2- microglobulin (β2M) genes was determined by SYBR Green I real-time PCR. Briefly, PCR was performed in a 20 μL total volume that contained 1 μL of cDNA, 9 μL of 2.5× SYBR Green I mix (Tiangen, Beijing, China), and 10 μmol/L primer pairs. After an initial denaturation at 95°C for 3 min, 45 cycles consisting of the following procedure was performed using an MJ Research DNA Engine Opticon 2 PCR cycler (BIO-RAD, USA):10 s at 95°C, 30 s at 64°C for β2M and ASF/SF-2, 60°C for TCRζ and ZAP-70, and 40 s at 60°C for FcεRIγ. The relative amount of the genes of interest and the β2M reference gene was measured in two independent assays. The data are presented as the relative expression of the genes of interest relative to the internal control gene as determined by the 2(−ΔΔCT) method [2, 34]. Additionally, the specific amplification of the PCR products was analyzed by melting curve analysis and agarose gel electrophoresis. The real-time PCR primers used for all of the gene amplifications were synthesized by Shanghai Biological Engineering Technology Services Co., Ltd. (Table 1).
Univariate analyses were performed using the Mann–Whitney test to compare the means of the differences in the mRNA expression between the CML and healthy control groups. Pearson correlation and linear regression analyses were used to estimate the correlation between age and the mRNA level of the different genes in the different samples using the SPSS 11.5 statistical software. A difference with a P < 0.05 was considered statistically significant.
TCRζ3′-UTR isoforms in CML
Characteristic expression of ASF/SF-2 in CML
Expression pattern of the ASF/SF-2, TCRζ, ZAP-70 and FcεRIγ genes in CML
The expression level of the TCRζ, FcεRIγ, ASF/SF-2, ZAP-70 genes was determined by real-time PCR using the SYBR Green I technique and quantitatively assessed by comparison with the β2M reference gene using cDNA from PBMCs collected from CML, CML-CR and healthy control samples. Each of the four genes could be detected in every sample. To establish proper real-time quantitative PCR reaction conditions, we used diluted Molt-4 cDNA to make relative standard curves. The results demonstrated that the high amplification efficiency of the four targeted genes was successful and consistent with that of the β2M reference gene. In addition, the specific amplification of the PCR products was confirmed by melting curve and agarose electrophoresis analysis. A single melting curve peak and the expected PCR products were confirmed, the PCR products of all of the genes were randomly selected and sent for sequencing, and the sequencing results were confirmed by BLAST analysis to compare with data in GenBank (data not shown).
The expression characteristics of the TCRζ, FcεRIγ, ASF/SF-2 and ZAP-70 genes are related to TCRζ 3'-UTR spliceosome
The ASF/SF-2, TCRζ, ZAP-70 and FcεRIγ gene expression is correlated in CML
A significant positive correlation of the ASF/SF-2 and FcεRIγ expression level was found in the healthy control and CML groups (r = 0.822 p < 0.001 and r = 0.334, p = 0.035, respectively).
Defects inTCR/CD3 signaling in CML
The TCR/CD3 complex plays a central role in T cell activation, and the alteration of any subunits in the complex may change the T cell activation level[7–10]. An abnormal TCR repertoire, lower thymic output function and lower CD3 gene expression have been described in CML[2–6]. Alternative CD3 gene expression levels may directly represent a characteristic of lower T cell activation[2–4]. In this study, the TCRζ expression level was detected in 40 patients with chronic phase CML and compared with CML in complete remission and healthy individuals. Similar to our previous study, we found that the TCRζ gene expression level in the CML group was significantly lower than that in healthy controls, and we further demonstrated that the TCRζ gene expression level may be increased in patients with CML who achieved complete remission. It is possible that the high number of CML cells in the blood may have influenced the results; however, our previous studies have demonstrated decreased expression of the gene and protein encoding the TCRζ chain in purified CD3 + T cells in chronic phase CML by quantitative real-time PCR and FCM, respectively. Thus, we used PMBC samples as a simple method to analyze the expression characteristics of the TCRζ chain and its related genes.
Unlike the TCRζ chain, which mediates signaling through ZAP-70, FcεRIγ mediates signaling by associating with the phosphorylated protein kinase Syk, which is 100-fold more potent than ZAP-70 and is preferentially recruited to the FcεRIγ receptor[12, 38–40]. Thus, FcεRIγ may substitute for deficiencies in the TCRζ chain. In this study, we analyzed the FcεRIγ gene expression level and its correlation with TCRζ gene expression in patients with CML. As expected, the FcεRIγ expression level was significantly increased in patients with CML, while its expression level was lower in patients who achieved complete remission. These data suggest that, in the context of CD3ζ down-regulation, FcεRIγ expression in CML is up-regulated to contribute to TCR signaling transduction in a manner similar to that of the conserved functional ITAM motif, which is a different immune status than that found in CLL, where the FcεRIγ expression level was not up-regulated and was not correlated with the TCRζ expression level. However, FcεRIγ expression level did not demonstrate negative correlation with TCRζ expression level in patients with CML, suggesting that apparent defects in T cell-mediated immunity are involved in alternative immune regulation in CML. When we further analyzed the correlation in the WT+AS+ and WT+AS- CML groups, we found that the negative-correlation remained in WT+AS+ CML group, and by combining the gene expression characteristics of the WT+AS- CML group, it is thought that the defects in immune regulation is apparent in the WT+AS- CML group due to the differential distribution of TCRζ-3′UTR spliceosomes. An interesting and significant positive correlation between the expression of TCRζ and FcεRIγ genes was found in the CML-CR group, and whether this is the result of an abnormal immune regulation status rather than immunodeficiency in patients with CML-CR remains an open question.
It is well known, ZAP-70 is a downstream factor that transduces TCR signals. In this study, the finding of a significant positive correlation between the expression level of the TCRζ and ZAP-70 genes in the healthy control, CML-CR and CML groups further supports the correlation of the TCRζ and ZAP-70 genes in T cell activation.
The molecular mechanism of decreased TCRζ expression in CML
A lower transduction of the TCR signal may be a common feature in hematological malignancies. The absence of the TCRζ chain not only influences the TCR expression on the cell membrane and the number of single-positive (CD4+ or CD8+) circulating T cells, it also impairs the proliferative response and mature T cell activation level[42, 43]. However, the mechanism of TCRζ deficiency in T cells in patients with cancer is unclear. To gain insight into the molecular mechanism of TCRζ deficiency in CML, we analyzed the distribution of the TCRζ 3'-UTR isoforms, which contribute to the regulation of TCRζ expression, and the ASF/SF-2 gene expression level, which regulates the alternative splicing of eukaryotic genes.
In general, the TCRζ mRNA stability is mainly influenced by its downstream 3'-UTR. While the 906 bp WT 3'-UTR plays an important role in TCRζ transcript stability, the 344 bp alternatively spliced 3'-UTRsignificantly influences the generation of the TCRζ[22, 23]. Interestingly, while we found that 35% of the CML samples in this study contained only the wild type TCRζ 3'-UTR isoform, the wild type and alternatively spliced TCRζ3'-UTRs isoform could be detected in all healthy individual and CML-CR samples. These results may account for the feedback regulation of the immune system in certain CML cases. Moreover, samples that contained only the wild type TCRζ 3'-UTR isoform demonstrated a high expression level for the ASF/SF-2, FcεRIγ, TCRζ and ZAP-70 genes, and based on this finding, we tried to characterized the different CML subgroups using the different expression patterns of the TCR signaling components. A definitive characteristic was found when comparing the gene expression pattern of the ASF/SF-2, FcεRIγ, TCRζ and ZAP-70 genes in the WT+AS-and WT+AS+ CML groups.
The involvement of ASF/SF2 in the post-transcriptional regulation of TCRζ was described in T cells from patients with SLE. ASF/SF2 binds to the 3'-UTR of the TCRζ mRNA and regulates a shift in alternative splicing from the AS to the WT isoform, which modulates TCRζ protein expression. Therefore, a higher ASF/SF2 expression level is correlated with a higher WT TCRζ3'-UTR expression level, which results in a higher TCRζ protein expression level. In this study, a significantly higher ASF/SF2 expression level was found in patients with CML who had a lower TCRζ level, prompting the question of whether there is feedback regulation in patients with CML similar to that for the enhanced FcεRIγ expression level. However, this feedback regulation was unable to recover the TCRζ expression level. Interestingly, significantly higher ASF/SF2 expression was found in the WT+AS-group as compared with the WT+AS+CML group, a result that is in agreement with the biological findings. No study has reported similar results; thus, further investigation of more samples with outcome follow up for patients with CML is required in future studies.
In conclusion, to our knowledge, this is the first study attempting to provide a global gene expression profile of the TCRζ related genes: FcεRIγ, ASF/SF-2 and ZAP-70, and the distribution characteristics of the TCRζ 3'-UTR isoforms in de novo CML and CML-CR patients with TCRζ defective. The preliminary data may indicate that defective TCRζ expression may be characterized in the WT+AS- and WT+AS+ CML subgroups with different gene expression patterns. The TCRζ 3'-UTR alternative splicing characteristics may be a novel immunological marker for the evaluation of the CML immune status. Moreover, ASF/SF-2 may also be a target for regulation by the immune system to overcome immunodeficiency in CML.
The study was supported by grants from the National Natural Science Foundation of China (No. 81100353, 81270604), the Natural Science Foundation of Guangdong Province, China (No. 9251063201000001), the Fundamental Research Funds for the Central Universities (No. 21611447, 21612116) and the Medical Science Foundation of Guangdong Province (A2011325).
- Smahel M: Antigens in chronic myeloid leukemia: implications for vaccine development. Cancer Immunol Immun. 2011, 60: 1665-1668.View ArticleGoogle Scholar
- Chen S, Yang L, Chen S, Li Y: TCR zeta chain expression in T cells from patients with CML. Hematology. 2009, 14: 95-100. 10.1179/102453309X385241.View ArticlePubMedGoogle Scholar
- Chen X, Woiciechowsky A, Raffegerst S, Schendel D, Kolb HJ, Roskrow M: Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol. 2000, 111: 817-825. 10.1046/j.1365-2141.2000.02415.x.PubMedGoogle Scholar
- Li Y: Alterations in the expression pattern of TCR zeta chain in T cells from patients with hematological diseases. Hematology. 2008, 13: 267-275. 10.1179/102453308X343482.View ArticlePubMedGoogle Scholar
- Li Y, Geng S, Du X, Chen S, Yang L, Wu X, Li B, Schmidt CA, Przybylski GK: Restricted TRBV repertoire in CD4+ and CD8+ T-cell subsets from CML patients. Hematology. 2011, 16: 43-49. 10.1179/102453311X12902908411634.View ArticlePubMedGoogle Scholar
- Li Y, Geng S, Yin Q, Chen S, Yang L, Wu X, Li B, Du X, Schmidt CA, Przybylski GK: Decreased level of recent thymic emigrants in CD4+ and CD8 + T cells from CML patients. J Transl Med. 2010, 8: 47-10.1186/1479-5876-8-47.PubMed CentralView ArticlePubMedGoogle Scholar
- Call ME, Wucherpfennig KW: The T cell receptor: critical role of the membrane environment in receptor assembly and function. Annu Rev Immunol. 2005, 23: 101-125. 10.1146/annurev.immunol.23.021704.115625.View ArticlePubMedGoogle Scholar
- Call ME, Pyrdol J, Wucherpfennig KW: Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplasmic reticulum. EMBO J. 2004, 23: 2348-2357. 10.1038/sj.emboj.7600245.PubMed CentralView ArticlePubMedGoogle Scholar
- Clevers H, Alarcon B, Wileman T, Terhorst C: The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol. 1988, 6: 629-662. 10.1146/annurev.iy.06.040188.003213.View ArticlePubMedGoogle Scholar
- Fischer A, de Saint Basile G, Le Deist F: CD3 deficiencies. Curr Opin Allergy Clin Immunol. 2005, 5: 491-495. 10.1097/01.all.0000191886.12645.79.View ArticlePubMedGoogle Scholar
- Fischer A, Pieard C, Chemin K: ZAP70: a master regulator of adaptive immunity. Semin Immunopathol. 2010, 32: 107-116. 10.1007/s00281-010-0196-x.View ArticlePubMedGoogle Scholar
- Enyedy EJ, Nambiar MP, Liossis SN, Dennis G, Kammer GM, Tsokos GC: Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum. 2001, 44: 1114-1121. 10.1002/1529-0131(200105)44:5<1114::AID-ANR192>3.0.CO;2-B.View ArticlePubMedGoogle Scholar
- Koyasu S, D’Adamio L, Arulanandam AR, Abraham S, Clayton LK, Reinherz EL: T cell receptor complexes containing Fc epsilon RI gamma homodimers in lieu of CD3 zeta and CD3 eta components: a novel isoform expressed on large granular lymphocytes. J Exp Med. 1992, 175: 203-209. 10.1084/jem.175.1.203.View ArticlePubMedGoogle Scholar
- Mozaffari F, Hansson L, Kiaii S, Ju X, Rossmann ED, Rabbani H, Mellstedt H, Osterborg A: Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol. 2004, 124: 315-324. 10.1046/j.1365-2141.2003.04789.x.View ArticlePubMedGoogle Scholar
- Chen S, Zha X, Yang L, Li B, Liye Z, Li Y: Deficiency of CD3gamma, delta, epsilon, and zeta expression in T cells from AML patients. Hematology. 2011, 16: 31-36. 10.1179/102453311X12902908411832.View ArticlePubMedGoogle Scholar
- Chowdhury B, Tsokos CG, Krishnan S, Robertson J, Fisher CU, Warke RG, Warke VG, Nambiar MP, Tsokos GC: Decreased stability and translation of T cell receptor zeta mRNA with an alternatively spliced 3'-untranslated region contribute to zeta chain down-regulation in patients with systemic lupus erythematosus. J Biol Chem. 2005, 280: 18959-18966. 10.1074/jbc.M501048200.View ArticlePubMedGoogle Scholar
- Jensen JP, Hou D, Ramsburg M, Taylor A, Dean M, Weissman AM: Organization of the human T cell receptor zeta/eta gene and its genetic linkage to the Fc gamma RII-Fc gamma RIII gene cluster. J Immunol. 1992, 148: 2563-2571.PubMedGoogle Scholar
- Pang M, Abe T, Fujihara T, Mori S, Tsuzaka K, Amano K, Koide J, Takeuchi T: Up-regulation of α E 7, a novel integrin adhesion molecule, on T cells from systemic lupus erythematosus patients with specific epithelial involvement. Arthritis Rheum. 1998, 41: 1456-1463. 10.1002/1529-0131(199808)41:8<1456::AID-ART16>3.0.CO;2-0.View ArticlePubMedGoogle Scholar
- Moulton VR, Tsokos GC: Alternative Splicing Factor/Splicing Factor 2 Regulates the Expression of the ζ Subunit of the Human T Cell Receptor-associated CD3 Complex. J Biol Chem. 2010, 285: 12490-12496. 10.1074/jbc.M109.091660.PubMed CentralView ArticlePubMedGoogle Scholar
- Giunchi L, Nocentini G, Ronchetti S, Bartoli A, Riccardi C, Migliorati G: TCR kappa, a new splicing of the murine TCR zeta gene locus, is modulated by glucocorticoid treatment. Mol Cell Biochem. 1999, 195: 47-53. 10.1023/A:1006925927551.View ArticlePubMedGoogle Scholar
- Takeuchi T, Tsuzaka K, Pang M, Amano K, Koide J, Abe T: TCR zeta chain lacking exon 7 in two patients with systemic lupus erythematosus. Int Immunol. 1998, 10: 911-921. 10.1093/intimm/10.7.911.View ArticlePubMedGoogle Scholar
- Moser KL, Neas BR, Salmon JE, Yu H, Gray-McGuire C, Asundi N, Bruner GR, Fox J, Kelly J, Henshall S: Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African American pedigrees. Proc Natl Acad Sci USA. 1998, 95: 14869-14874. 10.1073/pnas.95.25.14869.PubMed CentralView ArticlePubMedGoogle Scholar
- Nambiar MP, Enyedy EJ, Warke VG, Krishnan S, Dennis G, Kammer GM, Tsokos GC: Polymorphisms/Mutations of TCR-ζ-Chain Promoter and 3′Untranslated Region and Selective Expression of TCR ζ-Chain with an Alternatively Spliced 3′Untranslated Region in Patients with Systemic Lupus Erythematosus. J Autoimmunol. 2001, 16: 133-142. 10.1006/jaut.2000.0475.View ArticleGoogle Scholar
- Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD: Genome- wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science. 2003, 302: 2141-2144. 10.1126/science.1090100.View ArticlePubMedGoogle Scholar
- Black DL: Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem. 2003, 72: 291-336. 10.1146/annurev.biochem.72.121801.161720.View ArticlePubMedGoogle Scholar
- Cáceres JF, Stamm S, Helfman DM, Krainer AR: Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science. 1994, 265: 1706-1709. 10.1126/science.8085156.View ArticlePubMedGoogle Scholar
- Krainer AR, Conway GC, Kozak D: Purification and characterization of premRNA splicing factor SF2 from HeLa cells. Genes Dev. 1990, 4: 1158-1171. 10.1101/gad.4.7.1158.View ArticlePubMedGoogle Scholar
- Li XL, Manley JL: New talents for an old acquaintance: the SR protein splicing factor ASF/SF2 functions in the maintenance of genome stability. Cell Cycle. 2005, 4: 1706-1708. 10.4161/cc.4.12.2210.View ArticlePubMedGoogle Scholar
- Ge H, Manley JL: A protein factor, ASF, controls cell-specific alternative splicing of SV40 early premRNA in vitro. Cell. 1990, 62: 25-34. 10.1016/0092-8674(90)90236-8.View ArticlePubMedGoogle Scholar
- Fu XD: The superfamily of arginine/serine-rich splicing factors. RNA. 1995, 1: 663-680.PubMed CentralPubMedGoogle Scholar
- Sanford JR, Longman D, Caceres JF: Multiple roles of the SR protein family in splicing regulation. Prog Mol Subcell Biol. 2003, 31: 33-58.View ArticlePubMedGoogle Scholar
- Massiello A, Chalfant CE: SRp30a (ASF/SF2) regulates the alternative splicing of caspase-9 pre-mRNA and is required for ceramide-responsiveness. J Lipid Res. 2006, 47: 892-899. 10.1194/jlr.C600003-JLR200.View ArticlePubMedGoogle Scholar
- Lemaire R, Winne A, Sarkissian M, Lafyatis R: SF2 and SRp55 regulation of CD45 exon 4 skipping during T cell activation. EUR J IMMUN. 1999, 29: 823-837. 10.1002/(SICI)1521-4141(199903)29:03<823::AID-IMMU823>3.0.CO;2-C.View ArticleGoogle Scholar
- Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG: BCR-ABL1-independent P13Kinase activation causing imatinib-resistance. J Hematol Oncol. 2011, 4: 6-10.1186/1756-8722-4-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Moulton VR, Kyttaris VC, Juang YT: The RNA-stabilizing Protein HuR Regulates the Expression of Chain of the Human T Cell Receptor-associated CD3 Complex. J Biol Chem. 2008, 283: 20037-20044. 10.1074/jbc.M710434200.PubMed CentralView ArticlePubMedGoogle Scholar
- Huang L, Chen S, Zha X, Yang L, Li B, Yu Z, Wang L, Li Y: Expression feature of CD3, FcεRIγ and Zap-70 in patients with chronic lymphocytic leukemia. Hematology. 2012, 17: 71-75.View ArticlePubMedGoogle Scholar
- Zha X, Chen S, Yang L, Shi L, Li B, Wu X, Lu Y, Li Y: Up-regulated TCRζ enhances interleukin-2 production in T-cells from patients with CML. DNA Cell Biol. 2012, in pressGoogle Scholar
- Shiue L, Zoller MJ, Brugge JS: Syk is activated by phosphotyrosine-containing peptides representing the tyrosine-based activation motifs of the high affinity receptor for IgE. J Biol Chem. 1995, 270: 10498-10502. 10.1074/jbc.270.18.10498.View ArticlePubMedGoogle Scholar
- Oliver JM, Burg D, Wilson BS, McLaughlin JL, Geahlen RL: Inhibition of mast cell FcÂ«RI-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J Biol Chem. 1994, 269: 29697-29703.PubMedGoogle Scholar
- Taylor N, Jahn T, Smith S, Lamkin T, Uribe L, Liu Y: Differential activation of the tyrosine kinases ZAP-70 and Syk after FcgRI stimulation. Blood. 1997, 89: 388-396.PubMedGoogle Scholar
- Wang H, Kadlecek TA, Au-Yeung BB, Goodfellow HE, Hsu LY, Freedman TS, Weiss A: ZAP-70: an essential Kinase in T-cell signaling. Cold Spring Harb Perspect Biol. 2010, 2: a002279-10.1101/cshperspect.a002279.PubMed CentralView ArticlePubMedGoogle Scholar
- Baniyash M: TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol. 2004, 4: 675-687. 10.1038/nri1434.View ArticlePubMedGoogle Scholar
- Whiteside TL: Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immun. 1999, 48: 346-352.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.